<DOC>
	<DOCNO>NCT01628094</DOCNO>
	<brief_summary>This randomize , open-label , multicenter study evaluate safety , efficacy tolerability combination treatment RO5466731 , RO5190591 , ritonavir Copegus ( ribavirin ) without RO5024048 patient chronic hepatitis C genotype 1 . In Part 1 , treatment-na誰ve patient randomized receive treatment RO5466731 , RO5190591 plus ritonavir , Copegus , without RO5024048 . In Part 2 , treatment-na誰ve patient receive successful regimen Part 1 , reduce intensity regimen , patient previously experience null response interferon-based treatment add study .</brief_summary>
	<brief_title>ANNAPURNA : A Study The Combination RO5466731 , RO5190591 , Ritonavir Copegus ( Ribavirin ) With Without RO5024048 Patients With Chronic Hepatitis C Who Are Either Treatment-Na誰ve Have Previously Experienced Null Response Interferon-Based Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Chronic hepatitis C genotype 1 &gt; /= 6 month duration screen Part 1 Part 2 : Na誰ve treatment interferon ( pegylated nonpegylated ) . Patients participate study investigate directacting antiviral agent without interferon exclude Part 2 : Treatment experience patient previous null response treatment interferon contain regimen Liver biopsy noninvasive ( e.g . Fibroscan ) evaluation past 24 calendar month show absence cirrhosis incomplete/transition cirrhosis Body mass index ( BMI ) 18 35 kg/m2 inclusive body weight &gt; /= 45 kg Pregnant lactate woman male female partner pregnant lactate Decompensated liver disease impair liver function ( define protocol ) Cirrhosis incomplete/transition cirrhosis Non hepatitis C chronic liver disease Positive hepatitis B HIV infection History preexist renal disease History severe cardiac disease History neoplastic disease within last 5 year , except localize situ carcinoma skin History drug abuse within last year ; history cannabinoid use exclude Evidence alcohol abuse within 1 year screen consumption 2 unit alcohol per day Medical condition require use systemic corticosteroid Received warfarin anticoagulant 21 day immediately prior screening expect require warfarin anticoagulant study Anticipated use need significant medical treatment study use concomitant medication nutrient exclude protocol ( e.g . drug contraindicate ritonavir , hormonal method contraception )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>